Involvement of the [uPAR:uPA:PAI-1:LRP] complex in human myogenic cell motility.

The urokinase-type plasminogen activator system is a proteolytic system involved in tissue remodeling and cell migration. At the cell surface, receptor (uPAR)-bound urokinase (uPA) binds its inhibitor PAI-1, localized in the matrix, and the complex is internalized by endocytic receptors, such as the low-density lipoprotein receptor-related protein (LRP). We previously proposed a nonproteolytic role for the uPA system in human myogenic cell differentiation in vitro, i.e., cell fusion, and showed that myogenic cells can use PAI-1 as an adhesion matrix molecule. The aim of this study was to define the role of the uPA system in myogenic cell migration that is necessary for fusion. Using a two-dimensional motility assay and microcinematography, we showed that any interference with the [uPAR:uPA:PAI-1] complex formation, and interference with LRP binding to this complex, markedly decreased myogenic cell motility. This phenomenon was reversible and independent of plasmin activity. Inhibition of cell motility was associated with suppression of both filopodia and membrane ruffling activity. [uPAR:uPA:PAI-1:LRP] complex formation involves high-affinity molecular interactions and results in quick internalization of the complex. It is likely that this complex supports the membrane ruffling activity involved in the guidance of the migrating cell toward appropriate sites for attachment.

[1]  J. Henkin,et al.  gp330 on type II pneumocytes mediates endocytosis leading to degradation of pro-urokinase, plasminogen activator inhibitor-1 and urokinase-plasminogen activator inhibitor-1 complex. , 1995, Journal of cell science.

[2]  Y. Wei,et al.  Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. , 1997, The Journal of clinical investigation.

[3]  H. Chapman,et al.  Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. , 1997, Current opinion in cell biology.

[4]  S. Moestrup,et al.  Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. , 1992, The Journal of biological chemistry.

[5]  Z. Werb,et al.  Focalized proteolysis: spatial and temporal regulation of extracellular matrix degradation at the cell surface. , 1996, Current opinion in cell biology.

[6]  M. Leibovitch,et al.  Evidence of a non-conventional role for the urokinase tripartite complex (uPAR/uPA/PAI-1) in myogenic cell fusion. , 1997, Journal of cell science.

[7]  D. Strickland,et al.  The Very Low Density Lipoprotein Receptor Mediates the Cellular Catabolism of Lipoprotein Lipase and Urokinase-Plasminogen Activator Inhibitor Type I Complexes (*) , 1995, The Journal of Biological Chemistry.

[8]  D. Loskutoff,et al.  Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? , 1996, The Journal of cell biology.

[9]  P. Andreasen,et al.  Very Low Density Lipoprotein Receptor Binds and Mediates Endocytosis of Urokinase-type Plasminogen Activator-Type-1 Plasminogen Activator Inhibitor Complex (*) , 1995, The Journal of Biological Chemistry.

[10]  E Ruoslahti,et al.  RGD and other recognition sequences for integrins. , 1996, Annual review of cell and developmental biology.

[11]  B. Sobel,et al.  Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. , 1993, Thrombosis research.

[12]  S. Rosenberg,et al.  Identification of the urokinase receptor as an adhesion receptor for vitronectin. , 1994, The Journal of biological chemistry.

[13]  B. M. Mueller,et al.  Melanoma cell migration on vitronectin: Regulation by components of the plasminogen activation system , 1997, International journal of cancer.

[14]  P. Mignatti.  Extracellular matrix remodeling by metalloproteinases and plasminogen activators. , 1995, Kidney international. Supplement.

[15]  H. Kobayashi,et al.  Modulation of Urokinase-type Plasminogen Activator and Ovarian Cancer Cell Invasion by in Vitro Inhibition of Updated Version Citing Articles E-mail Alerts Inhibition of in Vitro Ovarian Cancer Cell Invasion by Modulation of Urokinase- Type Plasminogen Activator and Cathepsin B , 2022 .

[16]  F. Blasi.  Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness , 1993 .

[17]  K. Preissner,et al.  Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. , 1990, The Journal of biological chemistry.

[18]  S. Moestrup,et al.  Receptor‐mediated endocytosis of plasminogen activators and activator/inhibitor complexes , 1994, FEBS letters.

[19]  D. Belin,et al.  The plasminogen activator/plasmin system. , 1991, The Journal of clinical investigation.

[20]  M. Opas.  Cellular adhesiveness, contractility, and traction: stick, grip, and slip control. , 1995, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[21]  Gargi Maheshwari,et al.  Deconstructing (and reconstructing) cell migration , 1998, Microscopy research and technique.

[22]  J. Quigley,et al.  Serine protease and metallo protease cascade systems involved in pericellular proteolysis. , 1990, Cell differentiation and development : the official journal of the International Society of Developmental Biologists.

[23]  D. Ingber.  Tensegrity: the architectural basis of cellular mechanotransduction. , 1997, Annual review of physiology.

[24]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[25]  T. Mitchison,et al.  Actin-Based Cell Motility and Cell Locomotion , 1996, Cell.

[26]  F. Blasi.  Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness , 1993, BioEssays : news and reviews in molecular, cellular and developmental biology.

[27]  T. L. Moser,et al.  Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells. , 1995, The Biochemical journal.

[28]  D. Waltz,et al.  Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. , 1994, The Journal of biological chemistry.

[29]  K. Preissner,et al.  Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. , 1997, Experimental cell research.

[30]  R. Pardi,et al.  alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)- dependent internalization of the urokinase receptor , 1995, The Journal of cell biology.

[31]  K. Burridge,et al.  Focal adhesions, contractility, and signaling. , 1996, Annual review of cell and developmental biology.

[32]  Steingrimur Stefansson,et al.  The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin , 1996, Nature.

[33]  D. Cheresh,et al.  Vitronectin and its receptors. , 1993, Current opinion in cell biology.

[34]  D. Lauffenburger,et al.  Cell Migration: A Physically Integrated Molecular Process , 1996, Cell.

[35]  F. Blasi,et al.  Modulation of activities and RNA level of the components of the plasminogen activation system during fusion of human myogenic satellite cells in vitro. , 1992, Developmental biology.

[36]  S. Muhammad,et al.  Plasminogen Activator Inhibitor-1 Contains a Cryptic High Affinity Binding Site for the Low Density Lipoprotein Receptor-related Protein* , 1998, The Journal of Biological Chemistry.

[37]  F. Blasi,et al.  Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes , 1997, The EMBO journal.

[38]  G. Barlovatz-Meimon,et al.  Primary human muscle satellite cell culture: variations of cell yield, proliferation and differentiation rates according to age and sex of donors, site of muscle biopsy, and delay before processing. , 1997, Biology of the cell.

[39]  K. Preissner,et al.  The urokinase receptor is a major vitronectin-binding protein on endothelial cells. , 1996, Experimental cell research.

[40]  J J Fredberg,et al.  Urokinase receptor mediates mechanical force transfer across the cell surface. , 1995, The American journal of physiology.

[41]  S. Moestrup,et al.  Epithelial glycoprotein-330 mediates endocytosis of plasminogen activator-plasminogen activator inhibitor type-1 complexes. , 1993, The Journal of biological chemistry.

[42]  D. Ingber,et al.  Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading. , 1997, Journal of cell science.

[43]  J. Hoover-Plow,et al.  The cell biology of the plasminogen system , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[44]  J. Fallon,et al.  The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. , 1997, The Journal of clinical investigation.

[45]  F. Blasi.  uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? , 1997, Immunology today.